Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
HIF1A-dependent induction of alveolar epithelial PFKFB3 dampens acute lung injury
Christine U. Vohwinkel, … , Rubin M. Tuder, Holger K. Eltzschig
Christine U. Vohwinkel, … , Rubin M. Tuder, Holger K. Eltzschig
Published November 3, 2022
Citation Information: JCI Insight. 2022;7(24):e157855. https://doi.org/10.1172/jci.insight.157855.
View: Text | PDF
Research Article Metabolism Pulmonology

HIF1A-dependent induction of alveolar epithelial PFKFB3 dampens acute lung injury

  • Text
  • PDF
Abstract

Acute lung injury (ALI) is a severe form of lung inflammation causing acute respiratory distress syndrome in patients. ALI pathogenesis is closely linked to uncontrolled alveolar inflammation. We hypothesize that specific enzymes of the glycolytic pathway could function as key regulators of alveolar inflammation. Therefore, we screened isolated alveolar epithelia from mice exposed to ALI induced by injurious ventilation to assess their metabolic responses. These studies pointed us toward a selective role for isoform 3 of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3). Pharmacologic inhibition or genetic deletion of Pfkfb3 in alveolar epithelia (Pfkfb3loxP/loxP SPC-ER-Cre+ mice) was associated with profound increases in ALI during injurious mechanical ventilation or acid instillation. Studies in genetic models linked Pfkfb3 expression and function to Hif1a. Not only did intratracheal pyruvate instillation reconstitute Pfkfb3loxP/loxP or Hif1aloxP/loxP SPC-ER-Cre+ mice, but pyruvate was also effective in ALI treatment of wild-type mice. Finally, proof-of-principle studies in human lung biopsies demonstrated increased PFKFB3 staining in injured lungs and colocalized PFKFB3 to alveolar epithelia. These studies reveal a specific role for PFKFB3 in counterbalancing alveolar inflammation and lay the groundwork for novel metabolic therapeutic approaches during ALI.

Authors

Christine U. Vohwinkel, Nana Burns, Ethan Coit, Xiaoyi Yuan, Eszter K. Vladar, Christina Sul, Eric P. Schmidt, Peter Carmeliet, Kurt Stenmark, Eva S. Nozik, Rubin M. Tuder, Holger K. Eltzschig

×

Figure 2

Pharmacological inhibition of PFKFB3 exacerbates lung injury.

Options: View larger image (or click on image) Download as PowerPoint
Pharmacological inhibition of PFKFB3 exacerbates lung injury.
(A) Schema...
(A) Schematic of the experiment: C57BL/6 mice (matched for age, sex, and weight) received 70 mg/kg of PFKFB3 inhibitor 3PO i.p. 24 hours prior to ventilation, with the Ctrl group being ventilated with a PIP of 15 mbar and IMV group with a PIP of 45 mbar. The groups that were not treated with 3PO received vehicle (DMSO). After 4 hours of ventilation the lungs were removed. (B) BALF protein concentration was measured with Bradford Assay qPCR (n = 4/group). (C and D) IL-6 and CXCL1 mRNA expression in whole-lung tissue was determined by qPCR (n = 4/group). (E and F) Representative images of H&E-stained lungs and cumulative lung injury score, which is a combined score of cellular infiltrates, interstitial congestion and hyaline membrane formation, and hemorrhage (n = 4 each IMV, IMV+3PO, Ctrl groups; n = 3 Ctrl+3PO group). (B) Eight males and 8 females. (C–F) Seven males and 8 females. Data are represented as mean ± SD. **P < 0.01, ***P < 0.001. Data were analyzed with 1-way ANOVA with Tukey’s correction for multiple comparisons.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts